Reduction of Immune System Activation in HIV-1-Infected Patients Undergoing Highly Active Antiretroviral Therapy
| Autor: | Juan Macías, Antonio Núñez-Roldán, Miguel C. Leal, B. Sánchez, Eduardo Lissen, C. Rey, Amalia Rubio, Armando Sánchez-Quijano, Juan A. Pineda, Jaime M. Franco |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Microbiology (medical) Anti-HIV Agents medicine.medical_treatment Receptors Tumor Necrosis Factor Immune system Antigen Antigens CD Immunity Immunopathology medicine Humans Receptors Tumor Necrosis Factor Type II Acquired Immunodeficiency Syndrome Chemotherapy biology Tumor Necrosis Factor-alpha Beta-2 microglobulin HLA-DR Antigens General Medicine biology.organism_classification Infectious Diseases Cytokine Lentivirus Immunology HIV-1 Female beta 2-Microglobulin |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1435-4373 0934-9723 |
| DOI: | 10.1007/s100960050388 |
| Popis: | The aim of this work was to analyze the effects of highly active antiretroviral therapy on the chronically activated immune system of 26 antiretroviral-naive HIV-1-infected patients. Samples from baseline to week 24 or 36 of treatment were tested for serum levels of beta2-microglobulin, tumor necrosis factor alpha and soluble tumor necrosis factor alpha receptor type II, as well as for human leukocyte antigen-DR expression on T cells. After starting therapy, the mean HIV-1 RNA serum levels decreased and the mean CD4 + cell counts increased from baseline to week 36 (P0.001). Mean levels of tumor necrosis factor alpha receptor type II, tumor necrosis factor alpha and beta2-microglobulin as well as expression of human leukocyte antigen-DR were significantly reduced at the end of follow-up (P0.01). Deactivation kinetics of these parameters was similar in patients with CD4+ counts200 cells/microl at baseline versus those with CD4 + counts200 cells/microl at baseline, despite higher activation at baseline in the group with200 cells/microl. In summary, this study shows that highly active antiretroviral therapy is able to induce a strong deactivation of the immune system of HIV-1-infected patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink